Logo - PrRadicava® (edaravone) Oral Suspension 105 mg / 5 mL Logo - PrRadicava® (edaravone) IV infusion 30 mg / 100 mL

PrRADICAVA® Oral Suspension

A NEW FORMULATION CHOICE FOR YOUR PATIENT’S FIGHT AGAINST ALS

RADICAVA® Oral Suspension and RADICAVA® IV are indicated for the treatment of patients with amyotrophic lateral sclerosis (ALS).2

Image - Radicava Bottle

The experience of RADICAVA®

More than 9,000 people have been treated with (n=2,287) and RADICAVA® IV Infusion (n=6,767) in North America, of which 564 have been treated with RADICAVA® IV in Canada.1†*

Image - Radicava Bottle

*As of October 2022.
†Clinical significance is unknown.

1. Data on file. Mitsubishi Tanabe Pharma America, Inc.
2. RADICAVA® Product Monograph. Mitsubishi Tanabe Pharma America, Inc.; 2022.

Next: Pharmacokinetic study